HBeAg-negative chronic hepatitis B: Cost-effectiveness of peginterferon alfa-2a compared to lamivudine in Taiwan

Value in Health

Volumn 11, Issue 2, 2008, Pages 131-138

  Veenstra, David L ^a   Sullivan, Sean D ^a   Lai, Ming Yang ^b   Lee, Chuan Mo ^c   Tsai, Chia Ming ^d   Patel, Kavita K ^e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d Roche Products Ltd   (Taiwan)

^e HOFFMANN LA ROCHE INC   (United States)

Author keywords

Cost effectiveness; Hepatitis B; Lamivudine; Peginterferon; Taiwan

Indexed keywords

HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A;

ARTICLE; BILLING AND CLAIMS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; HEALTH SURVEY; HEPATITIS B; HUMAN; LIFE EXPECTANCY; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MEDICAL LITERATURE; MONOTHERAPY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SOCIOECONOMICS; TAIWAN; TREATMENT RESPONSE;

EID: 41549124533     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2007.00221.x     Document Type: Article

References (39)

1. Mohamed R, Desmond P, Suh DJ, et al. Practical difficulties in the management if hepatitis B in the Asia-Pacific region. J Gastroenterol Hepatol 2004 19 : 958 69.
2. Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: an update. J Gastroenterol Hepatol 2003 18 : 239 45.
3. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004 351 : 1521 31.
4. Chen CJ. Epidemiology characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol 1997 12 (Suppl. S294 308.
5. Statistics Center, Department of Health. Main Causes of Death by Cancer in Taiwan for the Year of 2003; Main Causes of Death in Taiwan for the Year of 2003. Available from: http://www.doh.gov.tw/statistic/index.htm [Accessed November 15, 2004].
6. Bureau of National Health Insurance press release. Medical Care of Liver Disease. November 11, 2003.
7. The European Association for the Study of the Liver (EASL) Jury. EASL international consensus conference on hepatitis B. J Hepatol 2003 38 : 533 40.
8. Rizzetto M, Volpes R, Smedile A. Response of pre-core mutant chronic hepatitis B infection to lamivudine. J Med Virol 2000 61 : 398 402.
9. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004 351 : 1206 17.
10. Briggs A, Sculpher M. An introduction to Markov modeling for economic evaluation. Pharmacoeconomics 1998 13 : 397 409.
11. Lin CC, Wu JC, Chang TT, et al. Long term evaluation of interferon α2b in the treatment of patients with HBeAg-negative CHB in Taiwan. J Viral Hepat 2001 8 : 438 46.
12. The 2002 Abridged Life Table in Taiwan-Fuchien Area from Ministry of the Interior, ROC. Available from: http://www.moi.gov.tw/stat/Life/tc915200.htm [Accessed November 15, 2004].
13. Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988 8 : 493 6.
14. Liaw YF, Tai DI, Chu CM, et al. Early detection of HCC in patients with CHB. A prospective study. Gastroenterology 1986 90 : 263 7.
15. Kao JH, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations of HBV increase risk of HCC in hepatitis B carriers. Gastroenterology 2003 124 : 327 34.
16. Lau DT, Everhart J, Kleiner DE, et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997 113 : 1660 7.
17. Internal Data from The Transplant Society of Taiwan. The Organ Transplantation registry in Taiwan. 2003.
18. Chen CL, Fan ST, Lee SG, et al. Living-donor liver transplantation: 12 years of experience in Asia. Transplantation 2003 75 : 6 11.
19. Bureau of National Health Insurance press release. Medical Care of Liver Disease (Taiwanese). May 4, 2004.
20. Rizzetto M. Efficacy of lamivudine in HBeAg-negative chronic hepatitis B. J Med Virol 2002 66 : 435 51.
21. Crowley SJ, Tognarini D, Desmond PV, Lees M. Cost-effectiveness analysis of lamivudine for the treatment of chronic hepatitis B. Pharmacoeconomics 2000 17 : 409 27.
22. Wong JB, Koff RS, Tine F, Pauker SG. Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995 122 : 664 75.
23. Pwu RF, Chan K. Cost effectiveness analysis of interferon α therapy in the treatment of chronic hepatitis B in Taiwan. J Formos Med Assoc 2002 101 : 632 41.
24. Kanwal F, Gralnek IM, Martin P, et al. Treatment alternative for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med 2005 142 : 821 31.
25. Santantonio T, Mazzola M, Miglietta A, et al. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000 32 : 300 6.
26. Tassopoulos NC, Volpes R, Pastore G, et al. Post lamivudine treatment follow-up of patients with HBeAg negative chronic hepatitis B [abstract]. J Hepatol 1999 30 (Suppl. 1 S1 8.
27. Bonino F, Rosina F, Rizzetto M, et al. Chronic hepatitis in HBsAg carriers with serum HBV-DNA and Anti-HBe. Gastroenterology 1986 90 : 1268 73.
28. Hadziyannis S, Bramou T, Alexopoulou A, Makris A. Immunopathogenesis and natural course of anti-HBe-positive chronic hepatitis with replicating B virus, in viral hepatitis and liver disease. In : Hollinger FB, Lemon SM, Margolis H, eds. Proceedings of the 1990 International Symposium on Viral Hepatitis and Liver Disease: Contemporary Issues and Future Prospects. Baltimore, MD : Williams & Wilkins, 1991.
29. Brunetto MR, Giarin MM, Oliveri F, et al. Wild-type and e antigen-minus hepatitis B and course of chronic hepatitis. Proc Natl Acad Sci USA 1991 88 : 4186 90.
30. Wong JB. Interferon treatment for chronic hepatitis B or C infection: costs and effectiveness. Acta Gastroenterol Belg 1998 61 : 238 42.
31. Bennett WG, Inoue Y, Beck JR, et al. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997 127 : 855 65.
32. Taiwan Bureau of National Health Insurance. Fee Schedule for Medical Service and Reference List for Drugs. 2004. Available from: http://www.nhi.gov. tw/06inquire/query1.asp [Accessed December 6, 2004].
33. Wang JD. Estimation of life years lost and financial burden of major cancer in Taiwan. Australia-Taiwan Clinical Trial Symposium, November 20-21, 2004, Taipei.
34. Chang Gung Memorial Hospital, Kaohsiung Statistics. Available from: http://www.clchen.org.tw [Accessed November 15, 2004].
35. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York : Oxford University Press, 1996.
36. Drummond MF, O'Brien BO, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes (2nd ed.). New York : Oxford University Press, 1997.
37. Mauskopf J, Rutten F, Schonfeld W. Cost-effectiveness league tables: valuable guidance for decision makers? Pharmacoeconomics 2003 21 : 991 1000.
38. Hsieh CR. Cost of chronic hepatitis B virus infection in Taiwan. J Clin Gastroenterol 2004 38 (Suppl. 3 S148 52.
39. Yang YK, Tarn YH, Wang TY, et al. Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs. Psychiatry Clin Neurosci 2005 59 : 385 94.